IRTC Quote, Financials, Valuation and Earnings

Masimo has a net margin of -19.35% compared to iRhythm Technologies's net margin of -45.89%. iRhythm Technologies's return on equity of -112.03% beat Masimo's return on equity of -39.91%.

iRhythm Technologies has a consensus price target of $137.33, signalling downside risk potential of -1.75%. On the other hand Masimo has an analysts' consensus of $182.07 which suggests that it could grow by 12.7%. Given that Masimo has higher upside potential than iRhythm Technologies, analysts believe Masimo is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Masimo has a beta of 1.229, suggesting its more volatile than the S&P 500 by 22.855%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Masimo quarterly revenues of $372M. iRhythm Technologies's net income of -$30.7M is higher than Masimo's net income of -$170.7M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.08x versus 4.44x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Outset Medical has a net margin of -19.35% compared to iRhythm Technologies's net margin of -86.66%. iRhythm Technologies's return on equity of -112.03% beat Outset Medical's return on equity of -140.06%.

iRhythm Technologies has a consensus price target of $137.33, signalling downside risk potential of -1.75%. On the other hand Outset Medical has an analysts' consensus of $22.25 which suggests that it could grow by 29.06%. Given that Outset Medical has higher upside potential than iRhythm Technologies, analysts believe Outset Medical is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $158.7M, which are larger than Outset Medical quarterly revenues of $29.8M. iRhythm Technologies's net income of -$30.7M is lower than Outset Medical's net income of -$25.8M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.08x versus 0.65x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -19.35% compared to iRhythm Technologies's net margin of 6.22%. iRhythm Technologies's return on equity of -112.03% beat Insulet's return on equity of 36.9%.

iRhythm Technologies has a consensus price target of $137.33, signalling downside risk potential of -1.75%. On the other hand Insulet has an analysts' consensus of $323.70 which suggests that it could grow by 2.94%. Given that Insulet has higher upside potential than iRhythm Technologies, analysts believe Insulet is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iRhythm Technologies pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than Insulet quarterly revenues of $569M. iRhythm Technologies's net income of -$30.7M is lower than Insulet's net income of $35.4M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while Insulet's PE ratio is 56.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.08x versus 10.58x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of -19.35% compared to iRhythm Technologies's net margin of 28.26%. iRhythm Technologies's return on equity of -112.03% beat ResMed's return on equity of 25.76%.

iRhythm Technologies has a consensus price target of $137.33, signalling downside risk potential of -1.75%. On the other hand ResMed has an analysts' consensus of $264.49 which suggests that it could grow by 6.8%. Given that ResMed has higher upside potential than iRhythm Technologies, analysts believe ResMed is more attractive than iRhythm Technologies.

iRhythm Technologies has a beta of 1.343, which suggesting that the stock is 34.347% more volatile than S&P 500. In comparison ResMed has a beta of 0.783, suggesting its less volatile than the S&P 500 by 21.661%.

iRhythm Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. iRhythm Technologies pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

iRhythm Technologies quarterly revenues are $158.7M, which are smaller than ResMed quarterly revenues of $1.3B. iRhythm Technologies's net income of -$30.7M is lower than ResMed's net income of $365M. Notably, iRhythm Technologies's price-to-earnings ratio is -- while ResMed's PE ratio is 27.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iRhythm Technologies is 7.08x versus 7.27x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.